HOME >> MEDICINE >> NEWS
Research Offers New Tool In Fight Against Prostate Cancer

ANN ARBOR---Research from the University of Michigan Comprehensive Cancer Center strongly suggests that PSA tests can reliably gauge the effectiveness of chemotherapy for advanced prostate cancer.

A reliable method of assessing a cancer patient's response to treatment is important. It shows doctors whether the prescribed therapy is working and allows them to quickly and confidently change the treatment plan when it's ineffective---and presumably improve the patient's quality of life as a result.

The U-M researchers studied 62 men with advanced prostate cancer and found that those whose PSA level declined 50 percent or more after eight weeks of chemotherapy had a significantly higher survival rate.

PSA screening tests are used to measure the level of a prostate-specific antigen in the blood---which indicates the presence of prostate cancer. They also have been used to gauge patients' response to cancer therapy, but that application has been controversial because opinions differ on its validity and precisely how to interpret test results.

The U-M researchers found that patients whose PSA levels declined at least 50 percent after eight weeks of chemotherapy survived for 91 weeks (median), compared with 38 weeks for those whose PSA level did not decline 50 percent.

The study is detailed in the May issue of the Journal of Clinical Oncology. It was conducted by David C. Smith, M.D.; Kenneth J. Pienta, M.D.; Rodney L. Dunn, M.S.; and Myla S. Strawderman, M.S.


'"/>

Contact: David Wilkins
wilkins@umich.edu
(734) 764-2220
University of Michigan
30-Apr-1998


Page: 1

Related medicine news :

1. Researchers search for first sign of congestive heart failure
2. Research offers hope of new treatments for liver damage
3. Research suggests possible blood test for multiple sclerosis
4. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
5. 2005 Award for Basic Research in Biological Mineralization
6. 2005 Craniofacial Biology Research Award
7. 2005 Research in Dental Caries Award
8. 2005 Research in Prosthodontics and Implants Award
9. 2005 Basic Research in Periodontal Disease Award
10. 2005 Research in Oral Biology Award
11. 2005 Pulp Biology Research Award

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Research Offers New Tool Fight Against Prostate Cancer

(Date:10/22/2014)... only 24 hours in a day, that doesn’t seem to be ... their busy schedules for exercise and fitness. Fortunately, one does not ... shape. Here are five ways you can reach your fitness and ... Commute , Consider riding a bike or taking the bus or ... If you must use your car to get to work, start ...
(Date:10/22/2014)... MA (PRWEB) October 22, 2014 ... new solutions for the treatment of bacterial infections, microbial ... Sinskey has joined its board of directors. , ... and Engineering Systems at The Massachusetts Institute of Technology, ... MIT faculty since 1968. Dr. Sinskey also holds positions ...
(Date:10/22/2014)... -- Two sisters in high school have developed ways ... Medha Krishen use electronic stethoscopes, which electronically amplify body ... patterns or heartbeats. Ilina, a senior at Port ... a way to detect early lung damage in people ... Ilina recorded one breath cycle each from 16 smokers, ...
(Date:10/22/2014)... 2014 (HealthDay News) -- Measures taken by Firestone officials ... Liberia may have limited the spread of the disease ... The Firestone Natural Rubber Co. provides health services to ... nearby densely populated communities. Between Aug. 1 and ... cases among those 80,000 people. That incidence rate of ...
(Date:10/20/2014)... The newly updated Worldwide Medical Market Forecasts ... facts, figures and forecasts on the global medical markets. ... categories the Worldwide Medical Market Forecasts to 2019 ... on the worldwide medical market to reveal key insights ... data for 2010-2019, covering each country market individually, allowing ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4
(Date:10/22/2014)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... focused on the development of oral drug delivery ... its Phase IIa clinical trial of ORMD-0801, the ... 1 diabetes. The trial was conducted in ... Food and Drug Administration (FDA) Investigational New Drug ...
(Date:10/22/2014)...   Surefire Medical , Inc., the developer of ... targeted delivery of embolization agents in minimally invasive direct-to-tumor ... John R. Daniels , MD of the University of ... Steven C. Katz , MD of the Roger ... Board (SAB).    "The role of the ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
Cached News: